Barclays PLC Galectin Therapeutics Inc Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Barclays PLC holds 54,634 shares of GALT stock, worth $80,311. This represents 0.0% of its overall portfolio holdings.

Number of Shares

54,634

Previous 28,587 91.11%

Holding current value

$80,311

Previous $79,000 10.13%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$0.87 - $3.0 $22,660 - $78,141	26,047 Added 91.11%	54,634 $71,000
Q3 2024 Nov 15, 2024	BUY	$2.04 - $2.86 $44,059 - $61,770	21,598 Added 309.03%	28,587 $79,000
Q2 2024 Aug 14, 2024	BUY	$2.13 - $4.2 $14,886 - $29,353	6,989 New	6,989 $15,000
Q4 2021 Feb 14, 2022	SELL	$2.07 - $3.8 $4,982 - $9,146	-2,407 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$2.59 - $4.15 $10,878 - $17,430	-4,200 Reduced 63.57%	2,407 $9,000
Q2 2021 Aug 13, 2021	SELL	$2.07 - $5.1 $50,688 - $124,883	-24,487 Reduced 78.75%	6,607 $21,000
Q1 2021 May 13, 2021	BUY	$1.96 - $2.57 $37,412 - $49,056	19,088 Added 158.99%	31,094 $68,000
Q4 2020 Feb 11, 2021	SELL	$2.24 - $2.87 $11,813 - $15,136	-5,274 Reduced 30.52%	12,006 $27,000
Q3 2020 Nov 12, 2020	SELL	$2.53 - $3.64 $9,540 - $13,726	-3,771 Reduced 17.91%	17,280 $46,000
Q2 2020 Aug 12, 2020	BUY	$1.66 - $3.15 $12,730 - $24,157	7,669 Added 57.31%	21,051 $64,000
Q1 2020 May 13, 2020	SELL	$1.51 - $3.0 $40,283 - $80,034	-26,678 Reduced 66.6%	13,382 $27,000
Q4 2019 Feb 10, 2020	BUY	$2.79 - $4.32 $56,324 - $87,212	20,188 Added 101.59%	40,060 $115,000
Q3 2019 Nov 14, 2019	SELL	$3.0 - $4.05 $2,748 - $3,709	-916 Reduced 4.41%	19,872 $72,000
Q2 2019 Aug 14, 2019	SELL	$3.61 - $5.0 $402,886 - $558,015	-111,603 Reduced 84.3%	20,788 $86,000
Q1 2019 May 15, 2019	SELL	$3.86 - $6.02 $162,938 - $254,116	-42,212 Reduced 24.18%	132,391 $677,000
Q4 2018 Feb 14, 2019	BUY	$3.43 - $5.74 $577,587 - $966,575	168,393 Added 2711.64%	174,603 $599,000
Q3 2018 Nov 14, 2018	BUY	$3.68 - $6.93 $11,098 - $20,900	3,016 Added 94.43%	6,210 $37,000
Q2 2018 Aug 14, 2018	SELL	$3.16 - $9.16 $53,495 - $155,069	-16,929 Reduced 84.13%	3,194 $20,000
Q1 2018 May 15, 2018	BUY	$3.78 - $5.97 $76,064 - $120,134	20,123 New	20,123 $96,000

Others Institutions Holding GALT

# of Institutions

112

Shares Held

9.93M

Call Options Held

3.78M

Put Options Held

5.27M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $87.4M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account